Mitochondria as a Drug Target in Ischemic Heart Disease and Cardiomyopathy

摘要: Ischemic heart disease is a significant cause of morbidity and mortality in Western society. Although interventions, such as thrombolysis percutaneous coronary intervention, have proven efficacious ischemia reperfusion injury, the underlying pathological process ischemic disease, laboratory studies suggest further protection possible, an expansive research effort aimed at bringing new therapeutic options to clinic. Mitochondrial dysfunction plays key role pathogenesis injury cardiomyopathy. However, despite promising mitochondria-targeted drugs emerging from laboratory, very few successfully completed clinical trials. As such, mitochondrion potential untapped target for cardiomyopathy therapies. Notably, there are number overlapping therapies both these diseases, novel one condition may find use other. This review summarizes efforts date targeting mitochondria therapy outlines drug targets this field.